# Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

> **NCT02623829** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 42 (actual)

## Conditions studied

- Post-operative Excessive Scarring

## Interventions

- **DRUG:** Botulinum Toxin
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02623829
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623829, "Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02623829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*